

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 13, 2015

---

**INTEGRA LIFESCIENCES HOLDINGS CORPORATION**

(Exact name of Registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**0-26224**  
(Commission  
File Number)

**51-0317849**  
(I.R.S. Employer  
Identification No.)

**311 Enterprise Drive**  
**Plainsboro, NJ 08536**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 7.01 Regulation FD Disclosure**

As previously disclosed, Integra LifeSciences Holdings Corporation (the “Company” or “Integra”) announced plans in November 2014 to spin off its spine business to Integra stockholders on a tax-free basis (the “spin-off”). The spin-off will create a new publicly traded company called SeaSpine Holdings Corporation (“SeaSpine”). In connection with the announcement of the spin-off, the Company also announced its determination to realign its segment presentation. Beginning in the First quarter of 2015, the Company will report in three segments, as follows:

- **Specialty Surgical Solutions**

The Company’s new Specialty Surgical Solutions segment will consist of its former U.S. Neurosurgery and U.S. Instruments segment, as well as a portion of the International segment. Products and services included in the Specialty Surgical Solutions segment will be dural repair, precision tools & instruments, tissue ablation, and services and repair.

- **Orthopedic & Tissue Technologies**

Orthopedic & Tissue Technologies will consist of the former U.S. Extremities segment and the portion of the former U.S. Spine and Other segments that will not be included in SeaSpine, and a portion of the former International segment. The Company’s products and services included in the new Orthopedic & Tissue Technologies segment will be regenerative technologies, lower extremities, upper extremities, and private label.

- **Spine**

The Company’s Spine segment will consist of the majority of the former U.S. Spine and Other business that, in connection with the spin-off, will be transferred to SeaSpine, as well as a portion of the former International segment. Upon completion of the spin-off, Integra will update its segment presentation to reflect its two remaining segments.

The Company has furnished with this report a presentation contained in Exhibit 99.1 including unaudited segment revenue information reflecting the Company’s new reportable segments for the year ended December 31, 2014 and for each of the quarterly periods in the years ended December 31, 2014 and 2013.

The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Exchange Act or the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Historical Segment Revenue Information (unaudited)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: April 13, 2015

By: /s/ Glenn G. Coleman  
Glenn G. Coleman  
Title: Corporate Vice President and  
Chief Financial Officer

EXHIBIT INDEX

Exhibit  
Number


Exhibit

99.1

Historical Segment Revenue Information (unaudited)



# Historical Segment Revenue: New Segments 2012 – 2014



# New Reporting Segments Information

---

In November 2014, Integra announced the strategic decision to spin off the orthobiologics and spinal fusion hardware business into a separate, publicly traded company called SeaSpine Holdings Corporation. Integra management believes that a stand-alone SeaSpine will be better positioned to compete by allowing the new management team to focus and dedicate resources to drive growth, and that this form of separation should enable both Integra and SeaSpine to grow faster separately than they would together.

As part of the same announcement, Integra announced that it would realign its existing five business segments into three new segments, each representing global organizations. As of January 1, 2015, the three new segments are called Specialty Surgical Solutions, Orthopedic & Tissue Technologies, and Spine. Specialty Surgical Solutions consists of our prior U.S. Neurosurgery and U.S. Instruments segments as well as a portion of the International segment. Orthopedic & Tissue Technologies is comprised of the former U.S. Extremities segment and a portion of both the U.S. Spine and Other and International segments. The third segment contains the majority of the former U.S. Spine and Other business that will be included in the newly created SeaSpine, which, until the spin-off, we will refer to as our Spine segment.

The unaudited historical revenue information for these segments is provided in the following slides. This new segment breakout aligns with the way in which we manage the company. Going forward, our commentary and guidance will correspond to these new segments until the completion of the spin-off, at which point our business will contain only the Specialty Surgical Solutions and Orthopedics & Tissue Technologies segments.

# Annual Revenue: 2012 – 2014

UNAUDITED  
(\$ in Thousands)

## Global Segment Revenues:

In thousands

	2012	2013	2014
<b>Specialty Surgical Solutions</b>	<b>\$ 464,169</b>	<b>\$ 463,296</b>	<b>\$ 554,872</b>
U.S.	334,168	332,781	399,538
International	130,001	130,515	155,334
<b>Orthopedics &amp; Tissue Technologies</b>	<b>218,972</b>	<b>225,737</b>	<b>235,539</b>
U.S.	174,256	180,664	190,932
International	44,716	45,073	44,607
<b>Spine</b>	<b>147,730</b>	<b>147,181</b>	<b>137,894</b>
U.S.	134,406	129,249	123,570
International	13,324	17,932	14,324
<b>Total Revenue</b>	<b>\$ 830,871</b>	<b>\$ 836,214</b>	<b>\$ 928,305</b>
U.S.	642,830	642,694	714,040
International	188,041	193,520	214,265

# Quarterly Revenue: 2013

UNAUDITED  
(\$ in Thousands)

## Global Segment Revenues:

In thousands

	Q1 13	Q2 13	Q3 13	Q4 13	2013
<b>Specialty Surgical Solutions</b>	<b>\$ 106,433</b>	<b>\$ 114,598</b>	<b>\$ 120,780</b>	<b>\$ 121,485</b>	<b>\$ 463,296</b>
U.S.	76,161	81,905	87,383	87,332	332,781
International	30,272	32,693	33,397	34,153	130,515
<b>Orthopedics &amp; Tissue Technologies</b>	<b>54,193</b>	<b>54,574</b>	<b>56,769</b>	<b>60,201</b>	<b>225,737</b>
U.S.	42,162	43,138	47,793	47,571	180,664
International	12,031	11,436	8,976	12,630	45,073
<b>Spine</b>	<b>36,026</b>	<b>36,375</b>	<b>35,697</b>	<b>39,083</b>	<b>147,181</b>
U.S.	31,696	32,123	31,379	34,051	129,249
International	4,330	4,252	4,318	5,032	17,932
<b>Total Revenue</b>	<b>\$ 196,652</b>	<b>\$ 205,547</b>	<b>\$ 213,246</b>	<b>\$ 220,769</b>	<b>\$ 836,214</b>
U.S.	150,019	157,166	166,555	168,954	642,694
International	46,633	48,381	46,691	51,815	193,520



# Quarterly Revenue: 2014


UNAUDITED  
(\$ in Thousands)

## Global Segment Revenues:

In thousands


	Q1 14	Q2 14	Q3 14	Q4 14	2014
<b>Specialty Surgical Solutions</b>	<b>\$ 127,195</b>	<b>\$ 137,516</b>	<b>\$ 137,499</b>	<b>\$ 152,662</b>	<b>\$ 554,872</b>
U.S.	90,447	99,379	101,403	108,309	399,538
International	36,748	38,137	36,096	44,353	155,334
<b>Orthopedics &amp; Tissue Technologies</b>	<b>54,589</b>	<b>57,954</b>	<b>58,616</b>	<b>64,380</b>	<b>235,539</b>
U.S.	43,280	47,079	48,056	52,517	190,932
International	11,309	10,875	10,560	11,863	44,607
<b>Spine</b>	<b>33,275</b>	<b>35,881</b>	<b>33,604</b>	<b>35,134</b>	<b>137,894</b>
U.S.	29,655	32,348	30,642	30,925	123,570
International	3,620	3,533	2,962	4,209	14,324
<b>Total Revenue</b>	<b>\$ 215,059</b>	<b>\$ 231,351</b>	<b>\$ 229,719</b>	<b>\$ 252,176</b>	<b>\$ 928,305</b>
U.S.	163,382	178,806	180,101	191,751	714,040
International	51,677	52,545	49,618	60,425	214,265

# Integra Historic Revenue Reporting Segments



(%) Shows percentages of 2014 Revenues

# Integra New Revenue Reporting Segments



(%) Shows percentages of 2014 Revenues